fda drug safety communication naion semaglutide 2025 Blinded by the drug? A vigilyze signal linking semaglutide to NAION fda drug safety communication naion
Description
Clients often receive guidance on how to administer the injection, rotate injection sites to avoid irritation, and track their progress
Expert Opinions and Future Directions 8
Multiple blood samples were collected from ear vein at 0 (pre-dose), 0.167, 0.333, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, and 144 hr post-dose
The information below is based on preclinical research and published clinical trial data
Br J Pharmacol 173:20952110
However, some patients experience significant side effects, including nausea, vomiting, or gastrointestinal discomfort
